Advertisement

Low endogenous estradiol levels are associated with elevated risk of cardiovascular disease mortality in young and middle-aged men in the United States

      Highlights

      • The association of total estradiol (E2) with cardiovascular disease (CVD) in men is inconsistent.
      • Most prior studies were performed among older men or patients with CVD.
      • There is limited information on racial/ethnic differences in the relation of E2 with CVD.
      • In this study of young and middle-age men, low levels of E2 were associated with high CVD mortality.
      • This elevated risk was largely limited to non-Hispanic White men.

      Abstract

      Background and aims

      Evidence for the association of total estradiol (E2) with cardiovascular disease (CVD) in young men is limited. We investigated the association of total E2 or free estradiol (FE2) and CVD mortality in a nationally representative multiracial sample of young and middle-aged men in the United States.

      Methods

      Data were from 954 men without CVD, cancer, diabetes and not on androgen therapy or taking anabolic steroids, who participated in the National Health and Nutrition Examination Survey (1988–1991), for whom E2 was measured, and were followed for mortality through to 2015. Fasting serum levels of E2 were measured using competitive electrochemiluminescence immunoassays. Free estradiol was estimated from the levels of estradiol, sex hormone binding globulin, and albumin. International Classification of Diseases codes were used to define CVD mortality. Cox regression models were used to calculate hazard ratios (HR) and 95% confidence intervals (CI).

      Results

      The average age of participants at baseline was 35.7 ± 11.6 years, with 11% and 6% reporting Black and Hispanic race and ethnicity, respectively. During a median follow-up of 25.2 years, 40 CVD deaths were recorded. Controlling for baseline demographic and CVD risk factors, and total testosterone levels, a 1 standard deviation decrement in log E2 (HR: 2.33, 95%CI: 1.11–5.00) or FE2 (HR: 1.89, 95%CI: 1.01–3.57) was associated with elevated risk of CVD mortality. This elevated risk was largely limited to non-Hispanic White men.

      Conclusions

      In this study, low levels of E2 or FE2 were associated with elevated risk of CVD mortality.

      Graphical abstract

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Grumbach M.M.
        • Auchus R.J.
        Estrogen: consequences and implications of human mutations in synthesis and action.
        J. Clin. Endocrinol. Metab. 1999; 84: 4677-4694
        • Russell N.
        • Grossmann M.
        Mechanisms in endocrinology: estradiol as a male hormone.
        Eur. J. Endocrinol./European Federation of Endocrine Societies. 2019; 181: R23-r43
        • Schneider G.
        • Kirschner M.A.
        • Berkowitz R.
        • et al.
        Increased estrogen production in obese men.
        J. Clin. Endocrinol. Metabol. 1979; 48: 633-638
        • Barrett-Connor E.
        • Khaw K.T.
        Cigarette smoking and increased endogenous estrogen levels in men.
        Am. J. Epidemiol. 1987; 126: 187-192
        • Choi J.W.
        • Ryoo I.W.
        • Hong J.Y.
        • et al.
        Clinical impact of estradiol/testosterone ratio in patients with acute ischemic stroke.
        BMC Neurol. 2021; 21: 91
        • Arnlöv J.
        • Pencina M.J.
        • Amin S.
        • et al.
        Endogenous sex hormones and cardiovascular disease incidence in men.
        Ann. Intern. Med. 2006; 145: 176-184
        • Haring R.
        • Teng Z.
        • Xanthakis V.
        • et al.
        Association of sex steroids, gonadotrophins, and their trajectories with clinical cardiovascular disease and all-cause mortality in elderly men from the Framingham Heart Study.
        Clin. Endocrinol. 2013; 78: 629-634
        • Vikan T.
        • Schirmer H.
        • Njølstad I.
        • et al.
        Endogenous sex hormones and the prospective association with cardiovascular disease and mortality in men: the Tromsø Study.
        Eur. J. Endocrinol./European Federation of Endocrine Societies. 2009; 161: 435-442
        • Yarnell J.W.
        • Beswick A.D.
        • Sweetnam P.M.
        • et al.
        Endogenous sex hormones and ischemic heart disease in men.
        The Caerphilly prospective study, Arteriosclerosis and thrombosis : a journal of vascular biology / American Heart Association. 1993; 13: 517-520
        • Abbott R.D.
        • Launer L.J.
        • Rodriguez B.L.
        • et al.
        Serum estradiol and risk of stroke in elderly men.
        Neurology. 2007; 68: 563-568
        • Menke A.
        • Guallar E.
        • Rohrmann S.
        • et al.
        Sex steroid hormone concentrations and risk of death in US men.
        Am. J. Epidemiol. 2010; 171: 583-592
        • Belladelli F.
        • Del Giudice F.
        • Kasman A.
        • et al.
        The association between testosterone, estradiol and their ratio and mortality among US men.
        Andrologia. 2021; 53e13993
        • Tivesten As
        • Vandenput L.
        • Labrie F.
        • et al.
        Low serum testosterone and estradiol predict mortality in elderly men.
        J. Clin. Endocrinol. Metab. 2009; 94: 2482-2488
        • Chan Y.X.
        • Knuiman M.W.
        • Hung J.
        • et al.
        Neutral associations of testosterone, dihydrotestosterone and estradiol with fatal and non-fatal cardiovascular events, and mortality in men aged 17-97 years.
        Clin. Endocrinol. 2016; 85: 575-582
        • Ohlsson C.
        • Barrett-Connor E.
        • Bhasin S.
        • et al.
        High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (Osteoporotic Fractures in Men) study in Sweden.
        J. Am. Coll. Cardiol. 2011; 58: 1674-1681
        • Vandenplas G.
        • De Bacquer D.
        • Calders P.
        • et al.
        Endogenous oestradiol and cardiovascular disease in healthy men: a systematic review and meta-analysis of prospective studies.
        Heart. 2012; 98: 1478-1482
        • Yeap B.B.
        • Alfonso H.
        • Chubb S.A.P.
        • et al.
        Older men an optimal plasma testosterone is associated with reduced all-cause mortality and higher dihydrotestosterone with reduced ischemic heart disease mortality, while estradiol levels do not predict mortality.
        J. Clin. Endocrinol. Metab. 2014; 99: E9-E18
        • Rohrmann S.
        • Nelson W.G.
        • Rifai N.
        • et al.
        Serum estrogen, but not testosterone, levels differ between black and white men in a nationally representative sample of Americans.
        J. Clin. Endocrinol. Metab. 2007; 92: 2519-2525
        • Richard A.
        • Rohrmann S.
        • Zhang L.
        • et al.
        Racial variation in sex steroid hormone concentration in black and white men: a meta-analysis.
        Andrology. 2014; 2: 428-435
        • Chadid S.
        • Barber J.R.
        • Rohrmann S.
        • et al.
        Age-specific serum total and free estradiol concentrations in healthy men in US nationally representative samples.
        J. Endocrine. Soc. 2019; 3: 1825-1836
        • Moore J.X.
        • Chaudhary N.
        • Akinyemiju T.
        Metabolic syndrome prevalence by race/ethnicity and sex in the United States, national health and nutrition examination survey, 1988-2012.
        Prev. Chronic Dis. 2017; 14: E24
        • Virani S.S.
        • Alonso A.
        • Aparicio H.J.
        • et al.
        Heart disease and stroke statistics—2021 update.
        Circulation. 2021; 143: e254-e743
        • Blackmore H.L.
        • Ozanne S.E.
        Programming of cardiovascular disease across the life-course.
        J. Mol. Cell. Cardiol. 2015; 83: 122-130
        • Nyante S.J.
        • Graubard B.I.
        • Li Y.
        • et al.
        Trends in sex hormone concentrations in US males: 1988-1991 to 1999-2004.
        Int. J. Androl. 2012; 35: 456-466
        • Rosner W.
        Free estradiol and sex hormone-binding globulin.
        Steroids. 2015; 99: 113-116
        • Winters S.J.
        • Gogineni J.
        • Karegar M.
        • et al.
        Sex hormone-binding globulin gene expression and insulin resistance.
        J. Clin. Endocrinol. Metab. 2014; 99: E2780-E2788
        • Zipf G.
        • Chiappa M.
        • Porter K.S.
        • et al.
        National Health and Nutrition Examination Survey: Plan and Operations, 1999-2010, Vital and Health Statistics. Ser. 1.
        Programs and collection procedures, 2013: 1-37
        • Vermeulen A.
        • Verdonck L.
        • Kaufman J.M.
        A critical evaluation of simple methods for the estimation of free testosterone in serum.
        J. Clin. Endocrinol. Metab. 1999; 84: 3666-3672
      1. Annual Update of the HHS Poverty Guidelines--HHS. Notice. vol. 60. Federal register, 1995: 7772-7774
        • Gunter E.W.
        • Lewis B.G.
        • Koncikowski S.M.
        Laboratory Procedures Used for the Third National Health and Nutrition Examination Survey (NHANES III), 1988-1994.
        1996
        • Vermeulen A.
        • Kaufman J.M.
        • Goemaere S.
        • et al.
        Estradiol in elderly men.
        Aging Male. 2002; 5: 98-102
        • Cooke P.S.
        • Nanjappa M.K.
        • Ko C.
        • et al.
        Estrogens in male physiology.
        Physiol. Rev. 2017; 97: 995-1043
        • Santen R.J.
        • Brodie H.
        • Simpson E.R.
        • et al.
        History of aromatase: saga of an important biological mediator and therapeutic target.
        Endocr. Rev. 2009; 30: 343-375
        • Liu Y.
        • Ding J.
        • Bush T.L.
        • et al.
        Relative androgen excess and increased cardiovascular risk after menopause: a hypothesized relation.
        Am. J. Epidemiol. 2001; 154: 489-494
        • Muniyan S.
        • Xi L.
        • Datta K.
        • et al.
        Cardiovascular Risks and Toxicity - the Achilles Heel of Androgen Deprivation Therapy in Prostate Cancer Patients.
        vol. 1874. Biochim Biophys Acta Rev Cancer, 2020188383
        • Nethander M.
        • Quester J.
        • Vandenput L.
        • et al.
        Association of genetically predicted serum estradiol with risk of thromboembolism in men: a mendelian randomization study.
        J. Clin. Endocrinol. Metabol. 2021; 106: e3078-e3086
        • Murphy E.
        • Kelly D.P.
        Estrogen signaling and cardiovascular disease.
        Circ. Res. 2011; 109: 687-696
        • Kim J.K.
        • Levin E.R.
        Estrogen signaling in the cardiovascular system.
        Nucl. Recept. Signal. 2006; 4e013
        • Kim C.
        • Halter J.B.
        Endogenous sex hormones, metabolic syndrome, and diabetes in men and women.
        Curr. Cardiol. Rep. 2014; 16: 467
        • Callou de Sá E.Q.
        • Feijó de Sá F.C.
        • e Silva Rde S.
        • et al.
        Endogenous oestradiol but not testosterone is related to coronary artery disease in men.
        Clin. Endocrinol. 2011; 75: 177-183
        • Zheng H.
        • Li Y.
        • Dai W.
        • et al.
        Role of endogenous estrogen on the incidence of coronary heart disease in men.
        Angiology. 2012; 63: 591-596
        • Tedeschi-Reiner E.
        • Ivekovic R.
        • Novak-Laus K.
        • et al.
        Endogenous steroid sex hormones and atherosclerosis of retinal arteries in men.
        Med. Sci. Mon. Int. Med. J. Exp. Clin. Res. : international medical journal of experimental and clinical research. 2009; 15: Cr211-216
        • Ritchey J.
        • Zhang H.
        • Karmaus W.
        • et al.
        Linearity assessment methods for sex steroid hormones and carrier proteins among men in the National Health and Nutrition Examination Survey (NHANES III).
        Steroids. 2014; 82: 23-28
        • Orwoll E.S.
        • Nielson C.M.
        • Labrie F.
        • et al.
        Evidence for geographical and racial variation in serum sex steroid levels in older men.
        J. Clin. Endocrinol. Metab. 2010; 95: E151-E160
        • Wang C.
        • Christenson P.
        • Swerdloff R.
        Clinical relevance of racial and ethnic differences in sex steroids.
        J. Clin. Endocrinol. Metab. 2007; 92: 2433-2435
        • Liu B.
        • Du Y.
        • Wu Y.
        • et al.
        Trends in obesity and adiposity measures by race or ethnicity among adults in the United States 2011-18: population based study.
        BMJ. 2021; 372: n365
        • Qiao Q.
        • Gao W.
        • Zhang L.
        • et al.
        Metabolic syndrome and cardiovascular disease.
        Ann. Clin. Biochem. 2007; 44: 232-263
        • Ohlsson C.
        • Nilsson M.E.
        • Tivesten A.
        • et al.
        Comparisons of immunoassay and mass spectrometry measurements of serum estradiol levels and their influence on clinical association studies in men.
        J. Clin. Endocrinol. Metabol. 2013; 98: E1097-E1102
        • Schooling C.M.
        Androgen activity, ischaemic heart disease and risk factors among men in NHANES III.
        Eur. J. Clin. Invest. 2013; 43: 1273-1281
      2. Centers for Disease Control and Prevention, NHANES I Epidemiologic Follow-Up Survey (NHEFS) Calibration Sample for NDI Matching Methodology, In.